Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization

Cancer Cell

Volumn 13, Issue 4, 2008, Pages 365-373

  Schmiedel, Judith ^a,b   Blaukat, Andree ^b   Li, Shiqing ^a   Knöchel, Thorsten ^b   Ferguson, Kathryn M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Merck Serono GmbH   (Germany)

Author keywords

CELLCYCLE; CHEMBIO; PROTEINS

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; MATUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; DIMERIZATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; INHIBITION KINETICS; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

EID: 41249094559     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.02.019     Document Type: Article

References (41)

1. Bier H., Hoffmann T., Hauser U., Wink M., Ochler M., Kovar A., Müser M., and Knecht R. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother. Pharmacol. 47 (2001) 519-524
2. Bouyain S., Longo P.A., Li S., Ferguson K.M., and Leahy D.J. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc. Natl. Acad. Sci. USA 102 (2005) 15024-15029
3. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D54 (1998) 905-921
4. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P.J., Leahy D.J., Lemmon M.A., Sliwkowski M.X., Ward C.W., and Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12 (2003) 541-552
5. CCP4 (Collaborative Computational Project, Number 4). The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50 (1994) 760-763
6. Cho H.S., and Leahy D.J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297 (2002) 1330-1333
7. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., and Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 (2003) 756-760
8. Dawson J.P., Berger M.B., Lin C.C., Schlessinger J., Lemmon M.A., and Ferguson K.M. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol. Cell. Biol. 25 (2005) 7734-7742
9. Dawson J.P., Bu Z., and Lemmon M.A. Ligand-induced structural transitions in ErbB receptor extracellular domains. Structure 15 (2007) 942-954
10. Emsley P., and Cowtan K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. D60 (2004) 2126-2132
11. Ferguson K.M. Active and inactive conformations of the epidermal growth factor receptor. Biochem. Soc. Trans. 32 (2004) 742-745
12. Ferguson K.M., Darling P.J., Mohan M.J., Macatee T.L., and Lemmon M.A. Extracellular domains drive homo- but not hetero-dimerization of ErbB receptors. EMBO J. 19 (2000) 4632-4643
13. Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J., and Lemmon M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 11 (2003) 507-517
14. Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., and Sliwkowski M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5 (2004) 317-328
15. Friedman L.M., Rinon A., Schechter B., Lyass L., Lavi S., Bacus S.S., Sela M., and Yarden Y. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 102 (2005) 1915-1920
16. Garrett T.P.J., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A., et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110 (2002) 763-773
17. Graeven U., Kremer B., Südhoff T., Killing B., Rojo F., Weber D., Tillner J., Unal C., and Schmiegel W. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br. J. Cancer 94 (2006) 1293-1299
18. Hubbard S.R., and Miller W.T. Receptor tyrosine kinases: Mechanisms of activation and signaling. Curr. Opin. Cell Biol. 19 (2007) 117-123
19. Johns T.G., Adams T.E., Cochran J.R., Hall N.E., Hoyne P.A., Olsen M.J., Kim Y.S., Rothacker J., Nice E.C., Walker F., et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J. Biol. Chem. 279 (2004) 30375-30384
20. Kettleborough C.A., Saldanha J., Heath V.J., Morrison C.J., and Bendig M.M. Humanization of a mouse monoclonal antibody by CDR-grafting: The importance of framework residues on loop conformation. Protein Eng. 4 (1991) 773-783
21. Kohda D., Odaka M., Lax I., Kawasaki H., Suzuki K., Ullrich A., Schlessinger J., and Inagaki F. A 40-kDa epidermal growth factor/transforming growth factor alpha-binding domain produced by limited proteolysis of the extracellular domain of the epidermal growth factor receptor. J. Biol. Chem. 268 (1993) 1976-1981
22. Kreysch, H.G., and Schmidt, J. (2004). Pharmaceutical compositions directed to Erb-B1 receptors. Merck Patent GMBH (DE), EP1549344. April 2004. WO 2004/032960 A1.
23. Kollmannsberger C., Schittenhelm M., Honecker F., Tillner J., Weber D., Oechsle K., Kanz L., and Bokemeyer C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 17 (2006) 1007-1013
24. Lawrence M.C., and Colman P.M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234 (1993) 946-950
25. Lemmon M.A., Bu Z., Ladbury J.E., Zhou M., Pinchasi D., Lax I., Engelman D.M., and Schlessinger J. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J. 16 (1997) 281-294
26. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J.W., Kussie P., and Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7 (2005) 301-311
27. Mendelsohn J., and Baselga J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 33 (2006) 369-385
28. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., and Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61 (2001) 4744-4749
29. Murthy U., Basu A., Rodeck U., Herlyn M., Ross A.H., and Das M. Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch. Biochem. Biophys. 252 (1987) 549-560
30. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110 (2002) 775-787
31. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Carter C.W., and Sweet R.M. (Eds). Macromolecular Crystallography Volume 276 (1997), Academic Press, New York 307-326
32. Rodeck U., Herlyn M., Herlyn D., Molthoff C., Atkinson B., Varello M., Steplewski Z., and Koprowski H. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologically mediated and effector cell-independent effects. Cancer Res. 47 (1987) 3692-3696
33. Rodeck U., Williams N., Murthy U., and Herlyn M. Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha. J. Cell Biol. 44 (1990) 69-79
34. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 (2000) 211-225
35. Seiden M.V., Burris H.A., Matulonis U., Hall J.B., Armstrong D.K., Speyer J., Weber J.D.A., and Muggia F. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol. Oncol. 104 (2007) 727-731
36. Socinski M.A. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: Current status of matuzumab and panitumumab. Clin. Cancer Res. 13 (2007) 4597-4601
37. Stanfield R.L., Zemla A., Wilson I.A., and Rupp B. Antibody elbow angles are influenced by their light chain class. J. Mol. Biol. 31 (2006) 1566-1574
38. Sundberg E.J., and Mariuzza R.A. Molecular recognition in antibody-antigen complexes. Adv. Protein Chem. 61 (2002) 119-160
39. Vajdos F.F., Adams C.W., Breece T.N., Presta L.G., de Vos A.M., and Sidhu S.S. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J. Mol. Biol. 320 (2002) 415-428
40. Vanhoefer U., Tewes M., Rojo F., Dirsch O., Schleucher N., Rosen O., Tillner J., Kovar A., Braun A.H., Trarbach T., et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 22 (2004) 175-184
41. Zhang X., Gureasko J., Shen K., Cole P.A., and Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125 (2006) 1137-1149